Quinidine, serum or plasma

Alphabetical Test listing

Quinidine, serum or plasma-994

  
Quinidine, serum or plasma
  
994
  
LAB994
  
MSO
  
Cardioquin
Duraquin
Quinaglute
Quinidex
Quinora
  
Serum
  
  
1.0 mL
  
0.3 mL
  

Peak

  • Quinidine sulfate - 1.5 hours after dose
  • Quinidine gluconate - 4 hours after dose

Trough

  • Immediately prior to next dose
  • After change in dose - one to two days
  
  1. Allow sample to clot
  2. Spin within two (2) hours of sample collection
  3. Transfer serum to a Transfer vial/tube with cap - 12mL (LabCorp), labelled as serum
  
Heparin plasma
  

Dk green heparin (Li or Na)

 

  

Immediately following collection, mix tube thoroughly by gentle inversion, 5 - 10 times, to prevent clotting

  
  1. Spin  within two (2) hours of sample collection
  2. Transfer plasma to a Transfer vial/tube with cap - 12mL (LabCorp), labelled as the appropriate plasma type
  

Transfer vial/tube with cap - 12mL (LabCorp)

  

Ambient (preferred) - 14 days

Refrigerated - 14 days

Frozen - 14 days

Freeze/thaw cycles - stable x3

  
  • Gel-barrier tube
  • Severe hemolysis
  • Lipemia
  • Icteric specimen
  
LabCorp Burlington (007831): R-NX
  
Mo - Fr, Su
  
3 days
  

Immunoassay (IA)

  

Therapeutic: 2.0 − 5.0 μg/mL

 

  

Potentially toxic: >5.0 μg/mL

  

This Class 1A drug is useful in both supraventricular and ventricular arrhythmias. It major uses are to maintain sinus rhythm after conversion of atrial flutter or fibrillation, to prevent ventricular tachycardia, and for long-term prophylaxis in patients with AV nodal reentrant tachycardia and automatic atrial tachycardia. Quinidine also has been used to prevent symptomatic premature supraventricular and ventricular complexes. Because it slows conduction and prolongs the refractory period of the accessory pathway and suppresses automaticity of ectopic pacemakers, quinidine may prevent recurrences of paroxysmal supraventricular tachycardia caused by reentry over a concealed pathway or AV reciprocating tachycardia associated with the Wolff-Parkinson-White syndrome. It also may slow the ventricular response to atrial flutter or fibrillation in the preexcitation syndrome. Quinidine is often preferred to procainamide for long-term therapy because elevated antinuclear antibody titers and drug-induced lupus are common during prolonged therapy with procainamide.

  
80194
  
Result 6694-4
  
05/23/2019
  
02/20/2024
  
02/20/2024